8Indexed trials
drug · Product Intelligence
Lurasidone
Pipeline Intelligence
Lurasidone: 8 indexed trials, 3 sponsors; 0 linked Orange Book patents and 5 FDA-linked events where matched.
3Sponsors
0Orange Book patent links
5FDA-linked events
Development evidence
NCT00615433Sumitomo Pharma America, Inc. · schizophreniaPHASE3
NCT01421134Sumitomo Pharma America, Inc. · depressionPHASE3
NCT01435928Sumitomo Pharma America, Inc. · schizophreniaPHASE3
NCT01485640Sumitomo Pharma America, Inc. · bipolar_disorderPHASE3
NCT01566162Sumitomo Pharma America, Inc. · schizophreniaPHASE3
NCT01575561Sumitomo Pharma America, Inc. · bipolar_disorderPHASE3
NCT03902613New York State Psychiatric Institute · depressionPHASE4
NCT05213143Marubeni Pharmaceuticals (Suzhou) Co., Ltd. · schizophreniaPHASE4
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALLURASIDONE HYDROCHLORIDE · 2024-12-06
FDA_APPROVALLURASIDONE HYDROCHLORIDE · 2023-06-09
FDA_APPROVALLURASIDONE HYDROCHLORIDE · 2021-05-13
FDA_APPROVALLURASIDONE HYDROCHLORIDE · 2020-12-28
FDA_APPROVALLURASIDONE HYDROCHLORIDE · 2019-01-03
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.